The efficacy and safety of indobufen versus aspirin in patients with acute myocardial infarction: a retrospective observational study
Expert Review of Clinical Pharmacology · 2026
DOI: 10.1080/17512433.2025.2611291 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Bryan Richard Sasmita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Aspirin, Myocardial Infarction, Platelet Aggregation Inhibitors. Die Arbeit nennt 36 Literaturangaben. Gefördert von: The Innovation Program for Doctoral Students of The First Affiliated Hospital of Chongqing Medical University.
Abstract (Originalsprache)
BACKGROUND: Dual antiplatelet therapy with aspirin and P2Y12 inhibitors is the first antiplatelet of choice for acute myocardial infarction (AMI), but alternatives are needed for patients at high bleeding risk or with aspirin intolerance/hypersensitivity. This observational study investigated the efficacy and safety of indobufen, a reversible COX-1 inhibitor, among AMI patients compared to those receiving aspirin. METHODS: We retrospectively enrolled 907 consecutive AMI patients treated between June 2021 and June 2024. The primary endpoints were GUSTO bleeding and MACE between aspirin and indobufen. RESULTS: Patients receiving indobufen were older and had higher rates of comorbidities such as type 2 diabetes, gastritis, and peptic ulcers (all p 0.05). Multivariate regression confirmed indobufen independently reduced GUSTO mild bleeding risk. Boruta and SHAP analyses identified antiplatelet therapy, particularly aspirin, as a predictor of GUSTO mild bleeding. CONCLUSIONS: Indobufen may be considered an alternative antiplatelet therapy for AMI patients with a high bleeding risk and/or aspirin intolerance/hypersensitivity, however, prospective studies are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Förderung
- The Innovation Program for Doctoral Students of The First Affiliated Hospital of Chongqing Medical University
Zitieren
APA
Sasmita, B. R., Xie, L., Li, Y., Li, Z., Xie, S., & Luo, S. (2026). The efficacy and safety of indobufen versus aspirin in patients with acute myocardial infarction: a retrospective observational study. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2611291
Vancouver
Sasmita BR, Xie L, Li Y, Li Z, Xie S, Luo S. The efficacy and safety of indobufen versus aspirin in patients with acute myocardial infarction: a retrospective observational study. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2025.2611291
BibTeX
@article{Sasmita2026,
author = {Sasmita, Bryan Richard and Xie, Linfeng and Li, Yuanzhu and Li, Zhu and Xie, Siyuan and Luo, Suxin},
title = {The efficacy and safety of indobufen versus aspirin in patients with acute myocardial infarction: a retrospective observational study},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
doi = {10.1080/17512433.2025.2611291}
}
EUVIMED